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ABSTRACT 
Based upon previous experiments [4,22,55] a hypothesis was 
formulated that the local release of serotonin (5-hydroxytryptamine) 
from tissue mast cells was required to elicit delayed-type hyper¬ 
sensitivity in mice. There is substantial evidence that sensitized 
T-lymphocytes interact with mast cells leading to mast cell release 
of serotonin. This serotonin causes the separation of endothelial 
cell junctions, allowing the diapedesis of bone marrow derived 
effector cells into the delayed-type hypersensitivity (DTH) reaction 
site. The present study was undertaken to further characterize 
the T-cell - mast cell interaction in DTH and to obtain an 
in vitro correlate for this interaction. 
There are at least four possible mechanisms by which T-cell - 
mast cell interaction, leading to serotonin release from mast cells, 
can occurs l)via a T-cell derived lymphokine-like material, 2)via 
T-cell interaction, either direct or by means of a soluble factor, 
with macrophages which then activate mast cells, 3)via IgE, or 
4)via a T-cell derived antigen specific molecule. Experiments with 
peritoneal exudate cells, a source of macrophages, revealed the 
presence of an inhibitor of background (spontaneous) serotonin 
release from mast cells along with some indirect evidence for the 
presence of a substance that could actually induce serotonin 
release. Other experiments identified an IgE-like substance on 
the surface of mast cells from mice immunized to optimally express 
DTH. Evidence was presented that this substance could be derived 
from T-cells. 
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INTRODUCTION 
Immunology, as a separate discipline, is a relative newcomer 
to the modern scientific world. Immunology has emerged as a specialized 
field of study and research only since the middle of the twentieth 
century. The earliest historical references to immunology in the 
western world, however, date back to the 18th century. Reports of 
successful immunization against the disease of smallpox were made 
by Lady Mary Wortley Montague in 1721 and by Edward Jenner in 1789. 
Immunology is now classically divided into two distinct, though 
often functionally complementary, systems: humoral (antibody) immunity 
and cell-mediated immunity. Less than one hundred years ago, the 
distinction between these two immunologic systems was not so evident. 
After Louis Pasteur's success with the attenuation of pathogens and 
with immunizations against anthrax and most notably rabies, two 
schools of thought emerged regarding immunity. One school was led 
by Elie Metchnikoff, the discoverer of phagocytosis, who in the 1880's 
espoused the theory that immunity was dependent on certain cells 
in the body. Support for the humoral theory of immunity came from 
the work of Emil von Behring who in the 1890's discovered that 
materials in the cell-free portion of blood, which were termed 
antitoxins, were capable of inactivating diphtheria and tetanus 
toxin. Eventually it became clear that both theories with regard to 
immunity were correct. Additional insight into cellular immunity 
came from the work of Robert Koch. Around the turn of the century, 
Koch described erythematous and indurated skin reactions which 
appeared some time after subcutaneous injection of tubercle bacilli 
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into guinea pigs already infected with the bacilli. Koch is thus 
credited with the discovery of delayed-type hypersensitivity 
reactions [9]. 
Delayed-type hypersensitivity 
Delayed-type (Type IV) hypersensitivity reactions (DTH) 
are the prototype of cell-mediated immunity. As was described 
by Koch, DTH reactions are classically associated with immuni¬ 
zation via infection with mycobacteria or with immunization 
augmented by water-in-oil emulsions containing mycobacteria 
(complete Freund's adjuvant). These reactions can be elicited 
by purified protein derivative of tuberculin (PPD), which is 
the antigen in mycobacteria most relevant to the expression of 
DTH responses, or by antigens that are administered with the 
mycobacteria. It has been well established that T (thymus derived)- 
lymphocytes play an integral role in DTH or cell-mediated 
reactions. B (Bursa of Fabricius eguivalent)-lymphocytes, in 
contrast, have been identified as being primarily responsible 
for antibody-mediated or humoral immune reactions. T-lymphocytes 
have been shown to have other functions such as helping B-cells 
produce antibodies, regulating and suppressing immune responses 
and mediating cytotoxicity. 
DTH reactions, elicited in guinea pigs previously infected 
with mycobacteria or immunized with complete Freund's adjuvant (CFA), 
are characterized macroscopically by erythema and induration, and 
microscopically by a predominance of mononuclear cells. There are, 
however, other types of delayed reactions which can be elicited 
in guinea pigs immunized with antigens administered in saline or 
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in non-mycobacteria containing water-in-oil emulsions (incomplete 
Freund's adjuvant). As compared to classic DTH or tuberculin 
reactions, these skin reactions are characterized by their lack 
of induration and their early disappearance after immunization 
and skin testing [10,11,42,50]. It was also noted that these 
delayed skin reactions were quite similar to reactions in humans 
called Jones-Mote reactions [50]. Jones-Mote reactions are delayed 
skin reactions produced in individuals previously immunized with 
protein antigens in saline [29,41], 
Basophils and mast cells 
An additional histologic feature of these delayed reactions 
induced by immunization without mycobacterial adjuvants is the 
prominent accumulation of basophils [18], Based upon this observa¬ 
tion, these delayed reactions have been termed cutaneous basophil 
hypersensitivity (CBH), as compared to the classic tuberculin- 
type reactions which essentially lack basophils [16]. Although 
being readily demonstrable in guinea pigs and in humans [64], 
CBH reactions have not been found to occur in mice. This finding 
has been attributed to the fact that mice essentially lack 
basophils [2]. Another interesting feature of this species has 
been the inability to elicit DTH reactions after flank skin 
testing in appropriately sensitized mice [2]. Good DTH reactions 
have, however, been obtained recently by testing in the ear skin 
(contact sensitivity [1]) or in the footpads [7], Histologic 
examination of the normal skin of mice revealed greater numbers 
of vasoactive amine containing mast cells in the ear skin and 
in the footpads as compared to the flank skin [22]. This was 

(5) 
one of the first hints that mast cells seemed to play a crucial 
role in DTH reactions in mice. 
Mast cells and basophils are similar in many respects. 
Both cells contain metachromatic granules in which vasoactive 
amines, such as histamine and serotonin (5-hydroxytryptamine), 
are stored. Both cells also possess Fc receptors on their surfaces 
which can bind IgE and certain subclasses of IgG via specialized 
domains in the Fc portion of these immunoglobulins. After this 
passive sensitization of the mast cell or basophil, if the proper 
multivalent antigen binds to the F ^ portion of the immunoglobulin, 
the antigen-antibody interaction then triggers the cell to de- 
granulate and release its vasoactive amines. This process is 
known as immediate (Type I) hypersensitivity. 
Mast cells are mononuclear cells that are normal inhabitants 
of various tissues, located preferentially around small blood 
vessels and near epithelial surfaces [45], Mast cells probably 
originate in the bone marrow from a mesenchymal precursor. Mast 
cells, however, do not develop in the bone marrow and do not 
circulate in the blood stream. They circulate in some immature 
form, enter the tissues, and differentiate into granule-containing 
cells [30]. The local environment in the tissue is believed to 
play an instrumental role in mast cell differentiation. Basophils, 
as opposed to mast cells, are polymorphonuclear leukocytes 
which arise in the bone marrow from the same stem cell as the 
other polymorphonuclear leukocytes, eosinophils and neutrophils 
[17], In contrast to mast cells, basophils are normally present 
in the bone marrow at different stages of development. A further 
distinction between basophils and mast cells is that basophils 
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are normally present in the blood, constituting approximately 
0.5% of circulating white cells in humans. Mast cells, on the 
other hand, are solely located in the extravascular tissue 
spaces. In pathologic conditions, CBH reactions demonstrate 
that specific immune stimuli can, however, recruit basophils 
to enter tissues. 
Role of mast cells in delayed-type hypersensitivity 
DTH reactions are characterized by erythema, induration, 
and mononuclear cell infiltrates. Histologic evidence in mice 
has revealed substantial numbers of mast cells in normal skin 
of sites (ear skin and footpads) that preferentially express 
DTH [22]* Further studies of mast cells in DTH have shown that 
the release of vasoactive amines from mast cells is reguired 
for the elicitation of DTH. The role of vasoactive amines was 
examined in mice depleted of serotonin by injection of reserpine. 
Murine mast cells contain both serotonin and histamine but 
serotonin seems to be the principle amine because the vasculature 
of mice is insensitive to histamine [55]. Reserpine depletes 
mast cells of serotonin by competitive displacement of serotonin 
from its binding sites in the granules. The serotonin is thus 
rendered susceptible to intracellular degradation by monoamine 
oxidase (MAO). Mice treated with reserpine are unable to express 
DTH [22]. However, MAO inhibitors which block the catabolism of 
intrqcytoplasmic serotonin have been shown to restore DTH in 
mice treated with reserpine [22]. This observation indicated 
that reserpine treatment did not adversely affect lymphocyte 
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function or any other aspect of DTH. The lack of serotonin 
was hence most likely responsible for the inability to elicit 
DTH. 
Other studies have also shown that the local release 
of serotonin (5-HT) is required to elicit DTH in mice. Anti¬ 
histamines were found to have no effect of DTH reactions, but 
cyproheptadine, a serotonin and histamine antagonist, inhibited 
these reactions [ 2 ]. Autoradiographic experiments have revealed 
. . . 3 
that tritiated serotonin ( H-5HT) was localized to tissue mast 
cells after systemic injection [22]. Further experiments showed 
3 
that H-5HT was depleted from mast cells m DTH, accompanied 
by the formation of gaps between endothelial cell junctions [ 4 ]. 
This observation was consistent with a previously described 
action of 5-HT to increase vascular permeability allowing the 
extravasation of various tracers into the extravascular space [36]. 
Role of T-lvmphocytes in delayed-type hypersensitivity 
Numerous lines of evidence have thus established the 
crucial role of mast cells in DTH; mast cell activation provides 
the necessary serotonin for the amine dependent diapedesis of 
bone marrow derived cells in DTH reactions. It is also well 
established that sensitized T-lymphocytes play a significant 
role in DTH. Upon antigenic challenge, T-cells release soluble 
products called lymphokines, some having the ability to recuit 
effector cells. Additional experiments have examined the role 
played by T-cells in DTH, particularly in regard to mast cell 
activation. A murine model of DTH was utilized for these studies0 
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Mice received an optimal immunization for the elicitation of 
DTH (0.2ml of 0.01% sheep erythrocytes [SRBC]). Four days later, 
the mice were tested for DTH by injecting SRBC into a footpad. 
The DTH response was quantitated by measuring footpad thickness 
before and after antigenic challenge [ 7]. 
The sheep erythrocyte DTH system has many similarities 
to cutaneous basophil hypersensitivity and Jones-Mote reactions. 
These three examples of DTH are delayed reactions, but in contrast 
to classic tuberculin reactions that are achieved by immunization 
with mycobacteria, they tend to be elicitable for only a short 
period of time after immunization. Using the SRBC model, DTH in 
mice was maximally elicitable four days after SRBC immunization 
but by 25 days, there was no detectable DTH reaction. It was 
postulated that this transient phenomenon was a result of 
effector T-cells with an intrinsic short life span [ 7]. 
The SRBC murine model of DTH has also been utilized to 
study the ability of immune cells to transfer DTH to non-immune 
recipients. In such experiments, donor mice were optimally 
immunized to express DTH with 0.01% SRBC. At day four, their 
spleen cells were harvested and transferred intravenously to 
syngeneic non-immune recipients. The recipients were then 
challenged with footpad injections of SRBC and were found to 
have significant DTH reactions [7]. Using autoradiography and 
electron microscopy, it has been demonstrated mast cells in 
recipients of immune spleen cells undergo activation with 5-HT 
release and endothelial cell changes, similar to those seen in 
actively sensitized animals [4]. 
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Other experiments involving the transfer of immune cells 
also support mast cell activation by T-cells in DTH. As mentioned 
previously, mice treated with reserpine are unable to express 
DTH. Immune spleen cells were unable to transfer DTH to non- 
immune recipients which were pretreated with reserpine. Reserpine 
treated mice, themselves unable to express DTH when skin tested, 
were, however, able to serve as cell donors for the transfer of 
DTH to non-immune recipients [22]. 
Further studies using these transfer technigues have 
uncovered additional evidence supporting the role of T-cells 
in DTH. Immune spleen cells were fractionated on a nylon wool 
column before transfer to non-immune mice. The fraction of 
non-adherent, non-immunoglobulin bearing lymphocytes from the 
column was presumed to contain only T-cells, being essentially 
void of B-cells. This fraction was able to transfer DTH responses 
to recipients, along with the capacity for mast cell activation, 
3 
as determined by the release of H-5HT, and for endothelial 
gap formation [4], 
Evidence against the involvement of B-lymphocytes in delayed- 
type hypersensitivity 
The SRBC model of DTH also provides evidence against the 
participation of B-cells. Four days after 0.01% SRBC immunization, 
when DTH was found to be optimally elicitable, B-cells were 
found to have not been stimulated by the SRBC immunization. 
This lack of stimulation was determined by noting a lack of 
antibodies against SRBC [ 6 ] and a lack of induction of antigen¬ 
binding, rosette-forming B-cells [14]. An immunization dose of 
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0.01% SRBC was found to selectively induce rosette-forming 
T-cells, while rosette-forming B-cells were actually suppressed 
below normal background levels [14]. Higher immunization doses, 
10% SRBC, however, selectively induced rosette-forming B-cells 
while suppressing rosette-forming T-cells [14]. These higher 
immunization doses also induce antibody formation. The functional 
role of these rosette-forming cells in the immune response is 
unknown. 
Further evidence against the involvement of B-cells in 
DTH comes from mice treated with anti-IgM antisera. These mice 
were rendered agammaglobulinemic and were unable to make antibody 
responses. These mice have, however, intact DTH responses [12,35]. 
Additional studies used mice immunized with high doses of SRBC (10%) 
and pretreated with B-cell depleting doses of cyclophosphamide. 
Mice receiving only high doses of SRBC have poor DTH responses; 
cyclophosphamide pretreatment in these animals augmented DTH 
responses by eliminating suppressor activity [ 7 ,22]. Mice 
receiving high doses of SRBC and cyclophosphamide have essentially 
no detectable antibody or B-cells. DTH responses of these mice 
did show mast cell activation with the formation of gaps between 
endothelial cells [ 4]• Thus the ultrastructural changes following 
mast cell activation in DTH were T-cell, not B-cell, dependent. 
Present study; In vitro interaction among mast cells, T-lymphocytes, 
macrophages, and antigen 
As the preceding studies have shown, considerable 
evidence has been accumulated in support of the hypothesis that 
after antigenic challenge, specifically sensitized T-cells 

(11) 
interact in some way with local mast cells. Mast cells then 
release serotonin which, in turn, causes the formation of gaps 
between endothelial cell junction, permitting the diapedesis 
of bone marrow derived cells to the site of antigenic challenge. 
This site is recognized macroscopically as a DTH reaction. 
It is interesting to note that T-cells are able to pass directly 
through the cytoplasm of endothelial cells, a process known as 
emperipolesiso Other circulating cells are only able to pass 
through gaps between endothelial cells to reach extravascular 
spaces [38], Another feature of T-cells is their ability, upon 
antigenic challenge, to secrete lymphokines, some of which are 
chemotactic for bone marrow derived leukocytes. As the experiments 
with serotonin antagonists have demonstrated, these chemotactic 
lymphokines along with the other lymphokines which increase 
vascular permeability [28] are not sufficient to produce the 
cellular infiltrates characteristic of DTH reactions. It thus 
appears crucial for T-cells to collaborate in some manner with 
mast cells for the elicitation of a DTH reaction. 
The present study focuses on this T-cell - mast cell 
collaboration. Based upon the information presented pertaining 
to the in vivo aspects of the T-cell - mast cell interaction, 
various experiments were performed attempting to identify this 
interaction in vitro. There are at least four possible mechanisms 
through which this collaboration,leading to mast cell activation 
in DTH, can occurs 1) via a T-cell derived lymphokine-like 
material, 2) via T-cell interaction, either direct or by means 
of a soluble factor, with macrophages which then activate 

mast cells, 3) via IgE, or 4) via a T-cell derived antigen specific 
molecule, "IgT," which possesses IgE-like activity. 
Hypothesis 1: A T-cell derived lymphokine activates mast cells 
in DTH 
The hypothesis that a T-cell derived product mediates mast 
cell activation is compatible with recent studies. A multitude 
of lymphokines have been described with a wide range of biologic 
activities [49]. A lymphocyte derived factor which possesses 
chemotactic properties for basophils has been identified [32,63]. 
As previously noted, basophils are in many respects quite similar 
to mast cells, both being involved in IgE dependent reactions [33] 
and in complement mediated reactions [24]. Both cells also play 
major roles in DTH (basophils in cutaneous basophil hypersensitivity) 
reactions. It has recently been demonstrated that supernatants 
generated from human mononuclear cell cultures were able to induce 
histamine release from basophils _in vitro. Production of this 
activity was stimulated by mitogens and by antigens that cause 
DTH skin reactions. These experiments have provided evidence 
for a collaboration between lymphocytes and basophils via a 
soluble mediator [58]. In a somewhat different system, it has 
been shown that the immunologic stimulation of human leukocytes 
in culture resulted in the release of soluble mediators that 
were able to augment IgE mediated histamine release [27]. 
To test for the presence of a lymphokine promoting mast 
cell activation, various supernatants were generated from the 
incubation of immune cells with antigens that are known to cause 
DTH reactions (PPD, SRBC). These supernatants were then incubated 

in vitro with mast cells. The assay for mast cell activation is 
described later. 
Hypothesis 2; Macrophages serve as an intermediary for T-cell 
activation of mast cells 
Another hypothesis for T-cell - mast cell interaction is 
that macrophages act as an intermediary between T-cells and mast 
cells. Macrophages play important roles in a variety of immunologic 
reactions [60,61]. Macrophages are reguired for T-cell production 
of lymphokines in response to antigenic stimulation. Before 
T-cells can recognize and respond to antigen, macrophages must 
first take up and process the antigen [62]. Physical association 
between T-cells and antigen-presenting macrophages is also reguired 
for T-cell proliferation [52]. This contact is probably mediated 
at some portion of the major histocompatibility complex because 
macrophages and T-cells must be syngeneic at the la locus of the 
H-2 MHC for optimal interaction to occur [53]. Since DTH responses 
are classically evoked by antigenic challenge in skin, much 
research has focused on identifying a macrophage-like cell in 
the skin. Cells residing within mammalian epidermis, Langerhans 
cells, have recently been shown to be related functionally to 
monocytes and macrophages [57]. 
To identify macrophage participation in the interaction 
between mast cells and T-cells, these three cells were incubated 
together and the assay for mast cell activation was performed. 
Peritoneal exudate cells, induced by the intraperitoneal injection 
of complete or incomplete Freund’s adjuvant, served as antigen- 
presenting cells. These cells have been shown to be proficient 
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in antigen presentation and in their ability to interact with 
lymphocytes [ 5]. Spleen cells from immunized mice served as the 
source of sensitized T-cells» 
Hypothesis 3: IqE mediates T-cell activation of mast cells 
Another proposed hypothesis is that IgE is the mediator 
for T-cell - mast cell interaction in DTH. IgE is known to bind 
to mast cells and immediate anaphylactic hypersensitivity is 
the result of mast cell degranulation caused by antigen combining 
with IgE. It has been demonstrated that after immediate-type 
hypersensitivity reactions, there is a late cutaneous phase with 
a delayed time course [ 3 ]• Various studies using immune serum 
transfers and testing with anti-IgE antibody have revealed that 
IgE mediated release of various vasoactive substances from 
cutaneous mast cells was involved in these late phase reactions 
[ 3 J. Thus IgE can play a role in skin reactions with a delayed 
time course. Another antibody, IgG^, has been observed to be able 
to mediate cutaneous basophil hypersensitivity [ 3 j. Thus B-cells 
and antibodies, in addition to T-cells, seem to also play a role 
in certain delayed reactions. The clinical implications and 
differences between antibody mediated and cell mediated delayed 
reactions are not fully appreciated. 
There is, however, a good amount of evidence against the 
participation of B-cells in the DTH model involving SRBC immunization 
and skin testing. As was presented earlier, DTH reactions were 
passively transferred with an enriched T-cell population after 
passage of immune spleen cells through a nylon wool column. 
Moreover, mice treated with B-cell depleting doses of cyclophosphamide 
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and immunized with large doses of SRBC were indeed able to 
express DTH. Furthermore, mice which were treated with anti-IgM 
antisera and rendered unable to mount an antibody response were 
also able to express DTH [12,35]. It is of course difficult to 
prove that all B-cells were eliminated by these technigues, and 
a few surviving B-cells may produce enough IgE to passively 
sensitize tissue mast cells. 
To detect antibody on the surface of mast cells, peritoneal 
cells containing 3% mast cells were collected from immunized mice 
and incubated with a multivalent antigen. Mice were immunized 
with 0.01% SRBC, an optimal dose for the elicitation of DTH [7 ], 
and then mast cells were isolated and incubated with SRBC, assaying 
for mast cell activation. In control experiments, mice were 
immunized with antibody inducing doses of SRBC or saline. In 
other experiments, these different kinds of mast cells were 
incubated with anti-mouse IgE antibody and anti-mouse IgG anti¬ 
body, attempting to detect, respectively, IgE and IgG on mast cell 
surfaces. 
Hypothesis 4: A T-cell derived antigen specific molecule mediates 
T-cell activation of mast cells 
The other proposed hypothesis is that T-cells interact 
with mast cells via a T-cell derived antigen specific molecule. 
T-cell recognition and interaction with antigens has for a long 
time been a subject of controversy. Immunoglobulin-like molecules 
have been isolated from T-cell membranes which appear distinct 
from B-cell membrane immunoglobulins on structural, functional, 
and serologic grounds [43]. Molecules on the surfaces of T-cells 
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have been found to possess idiotypic and immunoglobulin variable 
region frame-work determinants. These T-cell "receptors" have 
been discovered to also have antigen binding properties [20]. 
If this T-cell derived material had IgE-like properties also, 
it may be able to interact with mast cells. 
If a T-cell derived substance possessed IgE-like activity 
and was able to attach to mast cells, it may be detectable by 
incubating mast cells with SRBC (antigen) or possible with 
anti-mouse IgE antibody. An assay for mast cell activation could 
then be performed. Antigen and anti-IgE antibody were incubated 
with mast cells from mice immunized with an optimal dose for 
DTH elicitation or with an antibody inducing dose in the hope 
that the antigen or the anti-IgE antibody might detect more 
IgE-like material on mast cells after the DTH immunizing dose. 
Assay for mast cell activation 
The activation of mast cells by various agents has been 
3 
studies in vitro by the release of tritiated serotonin ( H-5HT) 
[13,37,44]. Mast cells constitute approximately 3% - 5% of the 
peritoneal cells in mice. Mast cells in the mixed peritoneal 
cell population have been shown to actively take up and con¬ 
centrate exogenous serotonin [44]. The ability of rat mast cells 
3 
to incorporate and release H-5HT has recently been used as an 
3 
assay for mediator release. The parallel release of H-5HT and 
endogenous histamine was observed after the incubation of mast 
cells with compound 48/80 [40], a non-specific mast cell 
secretogogue, or after the incubation of actively sensitized 
mast cells with antigen [56]. Other studies have shown release 

(17) 
3 
of H-serotomn from mouse mast cells by 48/80, Concanavalin A, 
and antigen and anti-mouse immunoglobulin using passively sensitized 
mast cells [37J. Regardless of whether 48/80 was incubated with 
whole peritoneal cell suspensions (3% - 5% mast cells) or 95% 
. . . 3 
purified mast cell suspensions, H-serotonm release was virtually 
identical [37]. This observation confirmed that only mast cells 
were being labelled by the tritiated serotonin. 
In these various studies, peritoneal mast cells, repre¬ 
senting 3% - 5% of the total cell population, were incubated with 
^H-5HT at 37°C. for varying amounts of time from 30 minutes [37] 
to three hours [13]. A 90 minute incubation seemed optimal for 
. . 3 
mast cell incorporation of H-5HT. The cells were then washed to 
. . . 3 
eliminate unincorporated H-5HT. Washing the cells one to four 
times before incubation with mast cell stimulators progressively 
lowered non-specific background release [13]. Three washes were 
3 
generally used to optimally reduce background release of H-5HT. 
The various stimulators of mast cell activation and mediator 
3 
release were then incubated with the H-5HT labelled mast cells. 
After the incubation period with the stimulators, the mast cells 
3 
were centrifuged and percent H-5HT release was calculated by 
dividing the total number of counts in the supernatant by the 
total number of counts in the supernatant and pellet. 
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MATERIALS AND METHODS 
Animals: Five-week old BDF^ male mice were obtained from Jackson 
Laboratories, Bar Harbor, Maine and were rested a minimum of 1 week. 
All mice used in experiments were between 6 and 10 weeks of age, 
weighing 25-30 grams. 
Induction of peritoneal exudate cells; 0.5ml of complete Freund's 
adjuvant (H37-Ra) or incomplete Freund's adjuvant (DIFCO Laboratories, 
Detroit, Michigan) was injected into the peritoneal cavity of mice. 
The CFA or IFA-induced peritoneal exudate cells (PEC) were harvested 
3 to 24 days after injection. CFA-SRBC-PEC were induced by injecting 
g 
1.5 x 10 SRBC IP one hour before sacrificing a mouse which had, 
5 days earlier, received 0.5ml of CFA IP. 
SRBC immunizationi Fresh sheep blood (Colorado Serum Company 
Laboratories, Denver, Colorado), stored in modified Alsevers solution 
and used within 2 weeks of delivery, was washed 3 times in sterile 
pyrogen free saline (Cutter Laboratories, Berkeley, CA) before in¬ 
jection. Mice were immunized by intravenous injection, via the retro- 
orbital plexus approached via the medial aspect of the eye, after being 
lightly anesthetized with ether. Mice were injected with 0.2ml of a 
0.01% suspension of SRBC in saline (an optimal dose for DTH) or 0.2ml 
of a 10% SRBC suspension (an antibody inducing dose). These immunization 
were used to generate both immune mast cells and immune spleen cells. 
Control animals were injected with 0.2ml of saline. 
Isolation of mouse peritoneal mast cells; Peritoneal mast cells were 
collected from normal BDF^ mice, or immune mice that had previously 
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received 0.01% SRBC or 10% SRBC IV, 4 or 18 days before sacrificing. 
The animals were sacrificed by cervical dislocation without anesthesia 
and 3 - 4ml of Locke's solution (NaCl-150mM, KCl-5mM, CaC^-lmM, 
HEPES (N-2-hydroxyethylpiperazine-N*-2-ethaLenlsulfonic acid)-5mM, 
glucose-5.5mM, BSA-0.1%, osmolality-305mosm, titrated to pH 7.0 
with NaOH) were injected into the peritoneal cavity. The abdomen 
was gently massaged for 60 seconds, and then the abdominal musculature 
was opened down the midline. The peritoneal cavity was opened and 
approximately 3.5ml of clear peritoneal fluid was withdrawn with 
a plastic pasteur pipette and introduced into a 50ml plastic Corning 
centrifuge tube. From this point on, all manipulations were performed 
at 4°C., including all centrifugations. The peritoneal cells were 
spun at 350 x g for 10 minutes and washed twice in Locke’s solution. 
Unless specified, all subsequent centrifugations were done at 
350 x g for 10 minutes (1200rpm in a Damon/IEC centrifuge, PR-6000, 
head radius of 23 centimeters). Platelets, as confirmed by micro¬ 
scopic examination of the peritoneal cells, were eliminated after 
the first spin. This step was important because only mast cells 
and platelets are known to incorporate exogenous serotonin. After 
these centrifugations, mast cells, lymphocytes, and other mononuclear 
cells were left in the pellet. For experiments such as those in 
Tables 4 and 5, where there was a possibility of some factor coating 
mast cells, only one wash was performed. The peritoneal cells were 
reconstituted in Locke's solution, and then counted in a hemocyto- 
meter with toluidine blue staining. Cell viabilities were determined 
by trypan blue exclusion. 
3 ■ 5 H-serotonin labelling of mast cells: Mast cells, 2 x 10 /ml, were 
3 
then incubated with H-5 hydroxytryptamine binoxalate (1.OmCurie/ 
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0.0082mg/l.0ml, New England Nuclear, Boston, MA) at a concentration 
of 5uCurie/10^mast cells in a 37°C. water bath for 90 minutes. 
After the incubation, the mast cells were washed three times to 
3 
eliminate unincorporated H-serotonin (5-HT). Only one wash was 
performed in Tables 4 and 5 because of the possibility of a factor 
coating the mast cells. The cells were then reconstituted so that 
5 0.5ml contained 10 mast cells which was then added to each assay 
tube (5ml polystyrene Falcon tubes, #2058, Oxnard, CA). In the 
various experiments, different supernatants, RBC, antibody, etc. 
were added to the mast cells and the total incubation volume was 
adjusted to 1ml with Locke's solution. The mast cells were, unless 
specified, incubated for 90 minutes in a 37°C. water batho 
48/80 (Sigma Chemicals), a non-specific mast cell secretogogue, 
and media controls were included in all experiments. 
3 
Determination of H-serotonin release: After the various mast cell 
incubations, the tubes were spun at 350 x g for 10 minutes. When 
mast cells were incubated with 1% SRBC or 1% HRBC, the assay tubes 
were spun at 450 x g (1500rpm, head radius of 23cm) for 10 minutes 
because of the increased size of the pellet. Each tube's supernatant, 
which had a volume of approximately 1ml, was poured off and divided 
evenly between two 5ml glass scintillation vials. The pellet was 
resuspended in 1ml of a 1% solution of Triton-X (New England 
Nuclear), vortexed, and also divided evenly between two scintillation 
vials. Thus each vial had approximately 0.5ml of supernatant or 
resuspended pellet. 3.5ml of Aquasol (universal liquid scintillation 
counting cocktail, New England Nuclear) was added to each vial. 
Each vial was then vortexed to obtain a homogeneous solution of 
the aqueous solution and Aquasol. The vials were then counted in 
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a Beckman J3-counter, (Model LS-330) for 1 minute. To calculate 
3 percent H-serotonin release, the average number of counts/minute 
3 
m the two supernatant vials, which represents H-5HT released from 
mast cells, was divided by the total number of counts, determined 
by adding the average counts/minute in the two supernatant vials 
and the average counts/minute in the two pellet vials. This method 
3 
used to calculate the percent H-5HT release does not require 
having the same number of mast cells in each assay tube. In a 
typical experiment, the average number of counts in the supernatant 
was in the thousands and the average number of counts in the pellet 
was in the tens of thousands. Vials containing scintillation fluid 
with Locke's solution had counts of less than 50. 
Incubation of ovalbumin-induced supernatants and mast cells: 
3 
Various supernatants were obtained for incubation with H-5HT 
labelled mast cells, attempting to identify a lymphokine-like 
material that caused 5HT release from mast cells. Ovalbumin- 
induced supernatants were generously supplied by Dr. Nancy Ruddle, 
Laboratory of Environmental and Public Health, Yale University, 
New Haven, CT. These supernatants were prepared by incubating 
inguinal lymph node cells with 250ug/ml of ovalbumin (OVA). The 
lymph node cells were harvested 8 days after subcutaneous in¬ 
jection of 50ug OVA + CFA into the tail of C57 B16 female mice. 
Supernatants were generated from a 24 hour incubation in a plate 
7 
or conical tube of LNC, 2 x 10 /ml, and antigen. These supernatants 
were originally generated for lymphotoxin measurement. The percent 
killing of A-9 fibroblasts for a 1:2 dilution of supernatants 
from the plate and conical tube incubations was respectively, 
69% and 39%. To assay for ^H-5HT release (Table 1), 500ul, 50ul, 
and 5ul of the two supernatants and media were added to 0.5ml of 
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3 H-5HT labelled mast cells and the volume in the various assay 
tubes was adjusted to 1ml with Locke's solution. Thus the different 
supernatant and media dilutions were Is 2, 1:20, and 1:200. The 
5 
final mast cell concentration was 10 cells/ml. The tubes were 
incubated for 90 minutes at 37°C. The tubes were then processed 
3 
as described above under determination of H-5HT release. 
Incubation of T-cell lymphoma and hybridoma supernatants and 
mast cells: These supernatants were also generously supplied by 
Dr. Ruddle. These supernatants were generated from T-cells from 
a lymphoma parent strain, BW5147, and from a hybridoma strain, 
64C11. These cells were previously sensitized to ovalbumin but 
were incubated for 48 hours in the absence of ovalbumin. The 
T-cells were incubated both with and without fetal calf serum 
in the media because different lymphokines are produced under 
the different media conditions. The supernatants generated after 
48 hours are known to contain various lymphokines, including 
3 lymphotoxm and interferon. For the H-5HT release from mast cell 
assay (Table 2), the supernatants and media controls were diluted 
in Locke's solution, incubated with mast cells for 90 minutes 
at 37°C., and processed as described earlier. 
Incubation of PEC and mast cells: CFA and IFA-PEC were induced 
as described earlier. The cells were harvested three days after 
IP injection (experiments shown in Figure 5) or five or nine days 
after injection (experiments shown in Figure 6) using sterile 
technigue. The PEC were harvested in the same manner as normal 
peritoneal cells except that the cells were isolated in Hanks' 
balanced salt solution (Grand Island Biological Company, Grand 
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Island, NY) + 10% FCS. The PEC were washed three times, counted, 
and brought up to 7 x 10^cells/ml in RPMI 1640 (GIBCO) supplemented 
with 5% FCS (Hy-Clone, heat inactivated. Sterile Systems, Inc., 
Logan,Utah), lOOIU/ml penicillin, lOOug/ml streptomycin, 75ug/ml 
gentamicin and 1% freshly thawed L-glutamine. Various concentrations 
of PPD (Connaught Medical Research Laboratories, Willowdale, Ontario), 
667, 250, 50 and 5 ug/ml,were added and the PEC + PPD were incubated 
in flat-bottomed circular wells with a diameter of 3 cm (Costar, 
Cambridge, MA) in a 37°C. CO^ incubator for 24 hours (Figure 5) 
or 48 hours (Figure 6). After the incubation, the PEC cultures 
were spun and aliquots of the different supernatants were taken 
and diluted along with the media in Locke’s solution. The super- 
3 
natant and media controls were then incubated with H-5HT labelled 
mast cells for 90 minutes at 37°C., and processed as described 
above. In Figures 5 and 6, 0.5ml of the different supernatants 
and media were added to 0.5ml of mast cells, hence a 1:2 supernatant 
dilution. The experiment shown in Figure 7 was performed similarly 
to those in Figures 5 and 6, except that the PEC + PPD incubations 
were carried out in 15ml Corning conical centrifuge tubes at a 
concentration of 15 - 20 x 10 PEC/ml or 6 x 10 cells/tube. 
Incubation of PEC and T-cell derived supernatants and subsequent 
incubation of the supernatant with mast cells: T-cell derived 
supernatants were generously supplied by Dr. Charles Janeway, 
Immunology Section, Department of Pathology, Yale University. 
These supernatants were generated from T-cell clones and hybridomas 
under various stimulatory conditions. T-cell supernatants were also 
supplied by Drs. Monte Meltzer and Edward J. Leonard, Biology Branch, 
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Cancer Center, National Institutes of Health. These supernatants 
were generated from the incubation of immune cells and antigen and 
are known to contain various lymphokines. In addition to incubating 
0.5ml of these supernatants directly with mast cells, these 
supernatants were also incubated with three day CFA and IFA-PEC 
in wells for 24 hours at 37°C. (Table 3). After this incubation, 
3 
these supernatants were then incubated with H-5HT labelled mast 
cells in 5ml Falcon tubes, and processed as described earlier. 
Incubation of mast cells, T-cells, antigen and macrophages? 
Spleen cells were used as the source of T-cells. Spleens from 
mice immunized 4 days earlier with either 0.2ml of 0.01% SRBC or 
0.2ml of 10% SRBC or saline were isolated, using sterile technigue. 
Spleens from a minimum of two animals were combined as a source 
for each type of immune or normal spleen cell. The spleens were 
sgueezed into a cell suspension between two glass slides, washed 
twice in HBSS + 10% FCS and brought up to 7 x 10^cells/ml in 
RPMI 1640 + 5% FCS, penicillin, streptomycin, gentamicin, and 
fresh L-glutamine. CFA-SRBC-PEC, induced and isolated as previously 
described, served as the source of antigen (free SRBC) and antigen- 
5 3 presenting cells or macrophages. 10 H-5HT mast cells were added 
to 1ml of each of the three kinds of spleen cells (0.01% SRBC, 
10% SRBC, and normal) and 1ml of CFA-SRBC-PEC. The different com¬ 
binations of these cells (Figure 8a) were centrifuged 350 x g 
for 10 minutes attempting to optimize cell-cell interaction, and 
incubated in the assay tubes for 90 minutes at 37°C. In a similar 
experiment (Figure 8c), the same protocol was followed except that 
the mast cells, CFA-SRBC-PEC and spleen cells were allowed to 

(25) 
settle in the tubes during a 24 hour incubation period. In another 
experiment (Figure 8c), CFA-SRBC-PEC + spleen cells were incubated 
for 24 hours in tubes. The supernatant and non-adherent cells 
5 3 
were then decanted off and 10 H-5HT labelled mast cells were 
spun down onto the adhered cells and incubated for 90 minutes at 
37°C. 
Interaction between RBC and mast cells: Mast cells from normal and 
immune mice (4 or 18 days after 0.01% SRBC or 4 days after 10% SRBC) 
3 
were isolated and labelled with H-5HT. 0.5ml of a 1% solution of 
7 
SRBC or HRBC in Locke's solution (5 x 10 RBC/ml) was added to 
105 mast cells in 0.5ml (100 fold excess of RBC). The RBC + mast 
cells were incubated under the following conditions: 1) pelleted, 
then 45 minutes at 4°C., 45 minutes at 37°C., 2) settling, 45 minutes 
at 4°C., 45 minutes at 37°C., 3) settling, 90 minutes at 37°C. 
These experiments (Table 4) attempted to identify an IgE-like 
material on the surface of mast cells from immunized mice. The 
first two incubation conditions were performed in an effort to 
simulate rosetting conditions. The mast cell, theoretically, would 
first interact with the RBC at 4°C., and then, this interaction 
would trigger the mast cell to release ^H-5HT at 37°C., a process 
known to require metabolic energy. 
Interaction between mast cells and anti-immunoglobulin antibody: 
Anti-DNP IgE was generously supplied by Dr. David H. Katz, Department 
of Cellular and Developmental Immunology, Scripps Clinic and Research 
Foundation, La Jolla, CA. The anti-DNP IgE was obtained from a 
murine hybridoma which secretes monoclonal IgE antibodies of 
anti-2,4-dinitrophenyl (DNP) specificity [34]. Rabbit anti-mouse 
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IgE, also supplied by Dr. Katz, was produced by immunizing a 
rabbit with the anti-DNP IgE hybridoma. Goat anti-mouse IgG was 
generously supplied by Dr. Robert Cone, Immunology Section, 
Department of Pathology, Yale University. This antibody was 
obtained by the affinity purification of antibody from goats 
immunized with mouse IgG. The final protein concentration was 
0.35mg/ml. The different antibodies were incubated with the 
previously described four different kinds of mast cells (Table 5). 
In one set of assay tubes, anti-DNP IgE (1:40 dilution of the 
stock) was incubated with the different mast cells for 45 minutes 
at 37°C. The tubes were then spun and the supernatant was poured 
off and saved to be counted later. The pellets were brought up 
in 1ml of Locke's solution and the rabbit anti-mouse IgE (1:40 
dilution of the stock) was added and incubated for an additional 
45 minutes at 37°C. Thus the anti-mouse IgE, in this case, was 
acting in a manner similar to antigen by bridging the anti-DNP 
3 IgE on the mast cell surface, triggering H-5HT release. 
Rabbit anti-mouse IgE and goat anti-mouse IgG were also 
added directly to the four kinds of mast cells to detect whether 
there was any immunoglobulin-like material already present on the 
mast cell surface. This material would be cross-linked by the 
antibody, thereby triggering mast cell degranulation. The mast 
cells were first incubated without any additive in Locke's solution 
for 45 minutes at 37°C. (corresponding to the anti-DNP IgE incu¬ 
bation) and then the rabbit anti-mouse IgE (1:40 dilution) or the 
goat anti-mouse IgG (1:40 dilution) were added and incubated for 
an additional 45 minutes. The tubes were then processed as described 
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earlier. 
Data analysis: All statistical comparisons were performed using 
the two-tailed Student's t-test. 
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RESULTS 
Profile of cell populations; 
(1) Normal peritoneal lavage cells - Mast cells constitute 
only a small fraction of the total cell population in the peritoneal 
lavage from a normal mouse. Using a lavage volume of 4m1 of Locke's 
6 
solution, approximately 3 x 10 cells are obtained per mouse; 
5 
30% lymphocytes, 67% other mononuclear cells, and 3% or 1 x 10 
mast cells. No polymorphonuclear leukocytes are observed in the 
lavage. Mast cells are detected by Wright-Giemsa or Toluidine blue 
stains (Figure 2). Viabilities, as measured by trypan blue exclusion, 
were greater than 97%. These counts did not vary significantly 
between normal or previously immunized mice. 
(2) Complete or incomplete Freund's adjuvant induced peritoneal 
exudate cells - Peritoneal exudate cells (PEC), induced by 0.5ml 
of IFA or CFA, were collected from three to 24 days after intra- 
peritoneal injection. 30 - 45 x 10^ PEC were obtained per mouse 
with viabilities of greater than 92%. The viability of the PEC 
obtained 24 days after injection was slightly less, approximately 
85%. The differential cell count of the PEC was; 30% mononuclear 
cells with vacuolated cytoplasm (henceforth termed macrophages), 
30% lymphocytes, and 40% neutrophils (Figure 2). PEC collected on 
different days after induction had similar counts except for a 
5 - 10% increase in lymphocytes seen 24 days after induction. 
There were no identifiable mast cells. 
O 
CFA-SRBC-PEC were induced by injecting 1.5 x 10 SRBC IP 
one hour before sacrificing a mouse which had, five days earlier, 
51 
received 0.5ml CFA IP. Previous studies with Cr-labelled SRBC 
showed phagocytosis of SRBC by the PEC. CFA-SRBC-PEC were similar 
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to CFA-PEC microscopically, except for the presence of free RBC. 
(3) Spleen cell population - 80 - 100 x 10^ spleen cells were 
obtained per mouse with viabilities of 80 - 90%. There were no 
morphologic differences between spleen cells from immune or non- 
immune animals. 
3 
Background H-serotonm release m Locke1s solution: The mean +_ 
3 
standard deviation background or spontaneous release of H-serotonin 
3 5 ( H-5HT) from mast cells (10 /ml in stationary round bottom 5ml poly¬ 
styrene tubes) was 3.5% + 1.4 using an incubation period of 90 minutes 
at 37°C. Figure 3 shows that the background release increased as 
the serotonin preparation aged, reaching 16% after five months of 
storage. For this reason, each serotonin batch was only used for 
two months to keep background release at a minimum. 
3 ... 
Background release of H-5HT from mast cells was significantly 
influenced by the media used for incubation. Incubation in RPMI 1640 
with 5% fetal calf serum caused a 3 - 5% increase in background 
spontaneous release above that obtained in Locke's solution. 
RPMI 1640 with 10% FCS caused a further increase of 2 - 3%. Thus 
it was always important to control for the particular media being 
used. It was noted that vigorous pipetting of labelled mast cells 
also tended to increase background release. Thus mouse mast cells 
were quite sensitive to manipulation. 
Positive controls: Compound 48/80, a non-specific mast cell 
secretogogue, was used as a positive control. Figure 4 shows that 
3 
higher concentrations of 48/80 caused greater H-5HT release. The 
actual percentage of serotonin release at the different [48/80] 
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was similar to the release of serotonin from rat mast cells [37]. 
3 
Total recoverable H-5HT, as determined by exposing labelled mast 
cells to a 60°C. water bath for 15 minutes, was 96%. 
Experiments attempting to identify a lymphokine-1ike material that 
caused serotonin release by mast cells: Based on the hypothesis 
that mast cells are activated in DTH via a T-lymphocyte derived 
lymphokine-1ike substance, various supernatants were generated 
in vitro from the interaction between immune cells and antigen. 
3 
These supernatants were then exposed to H-5HT labelled mast cells. 
In Table 1, two types of ovalbumin induced supernatants, one 
generated from incubation between lymph node cells and antigen in 
a plate, the other from incubation in conical tubes, were incubated 
with mast cells. These supernatants are known to contain lymphotoxin 
activity. Because of the possible presence of an inhibitor, different 
supernatant dilutions were tested in an effort to unmask an agonist 
effect. Results show essentially no difference between the media 
controls and the supernatants. The release caused by a 1:2 dilution 
of the supernatant from LNC + OVA was not significantly greater 
than the media control. The various dilutions were made in Locke's 
solution. Since the media used here (MEM + FCS) caused higher back¬ 
ground 5-HT release than Locke's, this probably explains the decrease 
in release at the higher dilutions. 
Table 2 shows serotonin release after mast cells were incubated 
with supernatants from various T-cell lymphomas and hybridomas, 
incubated without antigen. These supernatants are known to contain 
lymphotoxin and interferon activity. Media with and without serum 
were used because different lymphokines are produced by the hybridomas 

under the different media conditions. The results again show no 
significant release above background levels. 
The next set of experiments involved incubating CFA or IFA 
induced PEC with PPD, which is the antigen in mycobacteria relevant 
to the elicitation of DTH responses. The supernatants generated 
. . 3 
from these PEC cultures were then incubated with H-5HT labelled 
mast cells. As shown in Figure 5a, mast cell serotonin release 
after incubation with these supernatants was actually less than 
the background media release. The 5-HT release for the media without 
PPD and for media with the different PPD concentrations was 
8.3% + 0.5 (mean + S.D.). The mean 5-HT release after mast cell 
incubation with supernatants from IFA or CFA-PEC was 4.7% + 0.8. 
These results are significantly different (p<0.01, t-test). 
Figure 5b shows that this inhibition of spontaneous or background 
release was present at all [PPD] and in supernatants from PEC 
incubated without PPD. The inhibition also was independent of the 
type of PEC, whether induced by CFA or IFA. The mean inhibition 
for the two kinds of PEC at the different [PPD] was 43% + 9.6. 
In the experiment summarized in Figure 6a, five day and nine 
day CFA-PEC were incubated for 48 hours with PPD, twice as long 
an incubation period as the experiments in Figure 5. Again, there 
was a significant inhibition of background 5-HT release after 
mast cell incubation with the various PEC supernatants (p< 0.01, 
t-test). Figure 6b shows that the mean inhibition of background 
release was 44% + 6.3, essentially identical to the inhibition of 
43% +9.6 with 24 hour supernatants (Figure 5b). Thus based upon 
Figures 5 and 6, the inhibition is independent of antigen, independent 
of the type of PEC, and is apparent after culture periods of 24 or 
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48 hours. 
In the experiments depicted in Figures 5 and 6, the incubations 
between PEC and the antigen, PPD, were carried out in flat-bottomed 
circular wells with a diameter of 3cm at a cell concentration of 
0 
7 x 10 cells/ml. Recent reports [39,47,48] have demonstrated pro¬ 
duction of substantially higher titers of lymphokines (macrophage 
migration inhibitory factor) by incubating antigen with higher 
concentrations of immune cells and allowing them to settle in 
conical instead of round bottomed tubes. Using this information, 
C~\ *"7 
15 - 20 x 10 PEC/ml (6 x 10 cells/tube) were incubated with and 
without antigen in 15ml conical tubes for 48 hours (Figure 7) in an 
attempt to unmask the effects of a possible inhibitor by potentially 
increasing lymphokine production. Various dilutions of these super¬ 
natants were incubated with mast cells, again attempting to unmask 
the effects of a possible inhibitor. 
The data appearing in Figures 7a and 7b show a significant 
inhibition of background 5-HT release for the different PEC with 
and without PPD (p 40.02, t-test), with a mean inhibition of 
16% + 2.5. As was true in Figure 6, in Figure 7a the age of the 
PEC had no significant effect on the inhibition. The different 
supernatant dilutions did not uncover any agonist activity; the 
dilutions only had the expected effect of decreasing release at 
the higher dilutions. As was also seen in Figures 5 and 6, a 
comparison of Figures 7a and 7b shows sim^ilar inhibition independent 
of the presence of antigen. However, the mean inhibition of 16% + 3 
in Figure 7 is significantly less than the mean inhibition of 
44% + 8 in Figures 5 and 6 (p<0.01, t-test). Thus the different 
incubation conditions in Figure 7 (higher cell concentration. 
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incubation in conical tubes) must account for the decreased amount 
of inhibition. It is unclear whether this represents a decreased 
titer of an inhibitor or an increased titer of a potential lympho- 
kine which causes serotonin release from mast cells. 
Experiments attempting to identify macrophages as an intermediary 
in the activation of mast cells by T-cells; An alternate hypothesis 
to mast cell activation via a T-cell derived lymphokine is that 
T-cells must interact first with macrophages, either via direct 
contact or a factor, and it is the macrophage which then activates 
mast cells. The PEC used in the previous experiments were employed 
as a source of macrophages. 
In Table 3, various T-cell derived supernatants, obtained from 
Dr. Charles Janeway and Drs. Monte Meltzer and Edward J. Leonard, 
were incubated with mast cells. These supernatants are known to 
contain various kinds of lymphokines. Aliguots of these supernatants 
were also preincubated with CFA and IFA-induced PEC and then these 
supernatants were exposed to mast cells. Since the incubation 
conditions were similar to those in Figures 5 and 6, inhibition of 
background serotonin release from mast cells would be predicted 
with the media + PEC supernatant. The mean inhibition in Table 3 
for media + PEC compared to media is 43%, which is virtually 
identical to the inhibition of 44% in Figures 5 and 6. Inhibition 
of background release was also present in eight of eight instances 
when the various T-cell Hupernatants were first preincubated with 
PEC. This inhibition of background release was, however, present 
in varying amounts for the different supernatants. There is no 
reproducible difference between the inhibition induced by IFA-PEC 
or CFA-PEC. As was the case in Figure 7 where there was less 
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inhibition than in Figures 5 and 6, it is unclear why some supernatants in 
Table 3 caused less inhibition of background release than other 
supernatants. Possible explanations for this observation include 
a lower titer or partial destruction of the inhibitory factor, a 
change in the recognition or uptake of the inhibitory factor by the 
mast cells, or the presence of some factor with an agonist activity. 
In the experiments above, attempts were made to isolate various 
cell interactions in vitro in an effort to generate a factor causing 
mast cell secretion. Another protocol, which more closely reproduces 
the in vivo model of mast cell secretion in DTH, is to allow T-cells, 
antigen, macrophages and mast cells to interact directly. Spleen 
cells from animals receiving an optimal immunization for DTH 
elicitation (0.2ml of 0.01% SRBC) served as the source of T-cells. 
Normal spleen cells and spleen cells from animals receiving an 
immunization promoting antibody formation (0.2ml of 10?4 SRBC) were 
also used. CFA-SRBC-PEC which had been exposed to SRBC one hour 
prior to sacrificing the animal served as the antigen presenting 
3 
macrophages. In Figure 8a, H-5HT labelled mast cells were pelleted 
with the CFA-SRBC-PEC and spleen cells to facilitate cell-cell 
contact. The incubation period was 90 minutes. The results show 
serotonin release almost two times background release when either 
immune or normal spleen cells were incubated with mast cells, regardless 
of the presence of PEC. The incubation of PEC and mast cells caused 
serotonin release approximately egual to that of the media control. 
Since mast cells constitute only 3 - 5% of the peritoneal cells, 
efforts were made to maximize the probability of a mast cell coming 
into contact with an antigen presenting macrophage. In Figure 8b, 
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CFA-SRBC-PEC and spleen cells were preincubated for 24 hours in 
round bottom tubes. The supernatant and non-adhered cells were then 
poured off, and the mast cells were spun down onto the adhered cells 
(presumably antigen presenting macrophages. The results show inhibition 
of background 5-HT release for all the different combinations of 
spleen cells and macrophages. In Figure 8c, a similar protocol to 
that in Figure 8a was followed, except that the mast cells, macro¬ 
phages and spleen cells were incubated for 24 hours. With this 
long mast cell incubation period, the media background release, 28%, 
was considerably higher than in the 90 minute incubations. Interestingly, 
all the combinations of CFA-SRBC-PEC and immune or normal spleen 
cells, and PEC and the different types of spleen cells separately, 
showed strong inhibition of background release, with a mean inhibition 
of 54%. Based upon the three experiments in Figure 8, there is a 
progression from the modest agonist activity apparent after a 
90 minute incubation to the strong inhibition of background 5-HT 
release apparent after 24 hours. In both Figures 8b and 8c, maximal 
inhibition occurs with normal spleen cells by themselves, perhaps 
indirect evidence, when considered with the small amount of enhanced 
serotonin release seen in Figure 8a, supporting the presence of an 
agonist in the immune cells. 
Experiments attempting to identify an IgE-like material on mast cells: 
Another hypothesis for T-cell - mast cell collaboration is that an 
IgE-like material attaches to mast cells and, upon antigenic 
challenge, causes mast cell degranulation. Mast cells were collected 
from mice which had received the optimal immunizing dose for DTH 
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elicitation, 0.01% SRBC. It was decided to use a 100 fold excess 
7 
of SRBC (5 x 10 /ml = 1% SRBC) to assure erythrocyte contact with 
mast cells which constitute 3 - 5% of the peritoneal lavage. 
Day four 0.01% SRBC mast cells and normal mast cells were 
incubated with 1% SRBC and 1% HRBC under different conditions as 
depicted in Table 4a. It is important to note that the presence of 
. . . 3 
RBC in the pellet containing the H-5HT labelled mast cells interfered 
with the ability of the B-counter to detect radioactivity by a factor 
of approximately two. This is not significant in the comparison of 
individual data in Table 4 because RBC were present in all the 
assay tubes. However, to compare data in Table 4 to experiments 
done without RBC, it would be necessary to divide the serotonin 
percent release in Table 4 by two. This would convert the 5-HT 
release for normal mast cells + 1% RBC to about 5.5%, a figure 
compatible with the value for background release in Locke's 
solution in other experiments. When incubated with SRBC, mast cells 
from mice immunized to optimally express DTH had a significantly 
greater serotonin release, under all the incubation conditions, than 
mast cells from normal mice (pC 0.02, t-test). Mast cells from mice 
immunized with SRBC also had a significantly greater 5-HT release 
when exposed to HRBC as compared to normal mast cells (pC 0.02, 
t-test). This cross-reactivity was also seen under the various 
incubation conditions. 
Further studies were performed using different types of mast 
cells. Previous studies [ 7 ] have demonstrated good DTH reactions 
in mice four days after 0.01% SRBC immunization. DTH was, however, 
virtually undetectable 18 days after immunization. In addition. 
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mice four days after 10% SRBC immunization were shown to also have 
poor DTH reactions. Table 4b compares 0.01% SRBC immunized mice; 
mast cells were harvested four and 18 days after immunization. When 
incubated with SRBC, mast cells from mice 18 days after receiving 
optimal DTH elicitation doses (0.01% SRBC) released 8.2% serotonin 
compared to a mean of 16.6% for mast cells four days after immuni¬ 
zation. Thus the increase in serotonin release four days after 
immunization is transient, an observation consistent with the SRBC 
model for DTH [7 ]. The 5-HT release after SRBC incubation with mast 
cells from mice 18 days after 0.01% SRBC immunization is not signifi¬ 
cantly different from that for normal mast cells, 11.5%. The serotonin 
release after SRBC incubation with mast cells from mice previously 
immunized with 10% SRBC (an antibody inducing dose) was 10.7%, also 
not significantly different from normal mast cells. A 0.01% SRBC 
immunization thus seems to induce a material which coats mast cells 
and, upon antigenic challenge, cause 5-HT release. This property is 
highly reminiscent of IgE. This IgE-like material is transiently 
present on the surface of mast cells, not present after classic 
antibody inducing immunizing doses, and it cross-reacts with HRBC. 
Thus these in vitro experiments with the different kinds of 
mast cells appear to correspond to the in vivo SRBC model for DTH. 
There was an enhanced serotonin release after SRBC incubation with 
mast cells from mice four days after 0.01% SRBC immunization, a dose 
known to induce good DTH reactions. There was baseline serotonin 
release (equivalent to 1% SRBC + normal mast cells) from mast cells 
collected from mice 18 days after 0.01% SRBC immunization, or four 
days after 10% SRBC immunization, conditions known to result in 
poor DTH reactions. 

Further experiments using anti-immunoglobulin antibodies 
incubated with the various types of immune mast cells were performed 
to detect any antibodies on the surfaces of mast cells. The data 
is presented in Table 5. There is essentially no difference between 
the different types of mast cells in their ability to be stimulated 
by 48/80. When rabbit anti-mouse IgE was incubated with the various 
mast cells, the day four 0.01% SRBC mast cells, interestingly, 
showed the highest serotonin release, 29%. The same observation 
is true for the goat anti-mouse IgG, but at a much lower level, 5.3%. 
It is possible that the goat anti-mouse IgG is not specific for 
IgG, but is reacting with light chain determinants in the IgE-like 
material. It is unclear whether the anti-mouse IgE and anti-mouse 
IgG were actually detecting antibody on the surfaces of day four 
0.01% SRBC mast cells. The day 18 0.01% SRBC or the day four 10% SRBC 
mast cells might be expected to have more antibody on their surface 
because of, respectively, the longer period of time between 
immunization and testing, and the higher immunization dose. The 
anti-mouse IgE did cause increased release from the day 18 0.01% SRBC 
and the day four 10% SRBC mast cells as compared to normal mast 
cells. This enhanced release may represent antibody on the surfaces 
of these mast cells. The anti-mouse IgE is, however, clearly reacting 
more strongly to some immunoglobulin-like factor on the day four 
0.01% SRBC mast cells that is not present on the other types of 
mast cells. 
The results of Table 5 where the anti-mouse IgE and anti- 
3 
mouse IgG caused the greatest H-5HT release from the day four 
0.01% SRBC mast cells are similar to the results of Table 4b 
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where the SRBC also reacted maximally with the day four 0.01% SRBC 
mast cells. Thus the anti-mouse antibody studies provide additional 
evidence for an IgE-like material present on the surfaces of day four 
0.01% SRBC mast cells. 
A further observation from the antibody studies was that the 
day 18 0.01% SRBC mast cells seemed to be sensitized to the com¬ 
bination of anti-DNP IgE + anti-mouse IgE. Anti-DNP-IgE, when incubated 
by itself with mast cells, caused no increase in 5-HT release above 
background. When preincubated with anti-DNP IgE and then incubated 
with anti-mouse IgE, the day four 0.01% SRBC mast cells, the day four 
10% SRBC mast cells, and the normal mast cells released 3% - 6% 
more serotonin than they did without the anti-DNP IgE preincubation. 
However, when preincubated with anti-DNP IgE, the day 18 0.01% SRBC 
mast cells released 22% more serotonin after incubation with anti¬ 
mouse IgE. The etiology of this heightened sensitivity to antibody 
mediated serotonin release is uncertain. It may represent increased 
expression and/or synthesis of Fc receptors, or increased mast 
cell degranulation for a given amount of antibody - antigen inter¬ 
action 
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DISCUSSION 
Based on previous experiments [22,55] a hypothesis was 
formulated that the local release of serotonin from tissue 
mast cells was required to elicit delayed-type hypersensitivity 
in mice. Evidence has been presented that sensitized T-lymphocytes 
interact with mast cells leading to mast cell degranulation and 
release of serotonin. Subsequent experiments [ 4 ] have shown that 
the serotonin caused separation of endothelial cells to allow 
the diapedesis of bone marrow derived effector cells. The present 
study was undertaken to further characterize the T-cell - mast 
cell interaction in DTH, and to obtain an in vitro correlate for 
this interaction. 
Attempts to identify a lymphokine which causes serotonin release 
from mast cells 
Based on the hypothesis that a T-cell derived lymphokine 
caused serotonin release from mast cells, initial experiments 
tried to identify such a lymphokine. In Tables 1 and 2, super¬ 
natants were generated from immune lymph node cells in culture 
with antigen and from T-cell lymphoma and hybridoma cell lines. 
These supernatants were previously established to contain various 
3 
lymphokmes. When incubated with H-serotonm labelled mouse 
mast cells, these supernatants did not augment background 
(spontaneous) serotonin release. 
Identification of an inhibitor of background serotonin release 
from mast cells 
The next group of experiments utilized a heterogeneous 
population of cells; peritoneal exudate cells induced by complete 
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or incomplete Freund’s adjuvant. PEC contain almost equal numbers 
of neutrophils, lymphocytes and macrophages (mononuclear cells 
with vacuolated cytoplasm. Figure 2). Unexpectedly, when super¬ 
natants from cultures of PEC +_ PPD were incubated with mast cells, 
. . . . . . 3 
there was significant inhibition of background release of H-5HT 
(p< 0.01) (Figures 5 and 6). This inhibition was independent of 
the presence of antigen (PPD), independent of the type of PEC 
(whether induced by CFA or IFA), and was apparent after PEC culture 
periods of 24 or 48 hours. The mean inhibition of background 
release was 44%. Because of the heterogeneous cell population, 
it is unclear whether this inhibitory activity originated from 
the lymphocytes, neutrophils, or the macrophages. 
A recent report [59] has identified macrophages as playing 
a significant regulatory role in immune functions through the 
secretion of both enhancing and inhibiting factors. The system 
studied involved murine peritoneal natural killer (NK) cell 
activity against mouse lymphoma cells. A few days after the 
intraperitoneal injection of BCG (Mycobacterium bovis, strain 
Bacille Calmette-Guerin), an augmentation of the peritoneal 
NK activity was observed. It was found that BCG-induced peritoneal 
macrophages secreted large quantities of prostaglandin E^ (PGE2)» 
In vitro, PGE2 inhibited BCG-induced peritoneal NK cell activity. 
Further experiments revealed that indomethacin and aspirin 
significantly potentiated the BCG-induced enhancement of NK 
activity by inhibiting the synthesis of PGE2» Thus the macrophage 
appears to be crucial in regulating NK activity in BCG infected 
mice via both enhancing and inhibitory factors. 
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In another system [25,26], somewhat more analogous to the 
secretion of vasoactive amines, an inhibitor of histamine release 
was isolated from eosinophils. In this system, eosinophil-rich 
fractions of human leukocytes were incubated with specific allergen 
or anti-IgE. The cell-free supernatants were then incubated with 
human leukocytes assaying for the inhibition of anti-IgE induced 
histamine release. This inhibition was found to be related to 
prostaglandin because indomethacin blocked the immune release of 
the inhibitor from eosinophils. Thus it appears that eosinophils, 
as well as macrophages, can assume a regulatory role in the 
immune system. 
PGE^ and have been shown to be important regulators 
of immune responses by modifying antibody production, the mitogenic 
stimulation of lymphocytes, and delayed hypersensitivity reactions 
[23], Mouse peritoneal macrophages have been demonstrated to 
synthesize prostaglandin E [31]. It is thus possible that the 
factor inhibiting the background release of serotonin from mast 
cells may be related to a prostaglandin originating from peritoneal 
macrophages. An interesting follow-up experiment would be to 
incubate the PEC in the presence of a prostaglandin synthesis 
inhibitor (a cyclooxygenase inhibitor), such as indomethacin or 
. . . . 3 
aspirin, and then incubate the supernatant with H-5HT labelled 
mast cells. It is possible that by abolishing the inhibitory 
activity, a material with agonist activity may become evident. 
The experiments depicted in Figure 7 are similar to those 
in Figures 5 and 6 except that the PEC were incubated at higher 
cell concentrations and in conical tubes instead of flat-bottomed 
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wells. Certain experiments have demonstrated the critical need 
for achieving intimate cell-cell contact. In vivo reactions, 
such as DTH, occur in stable and highly organized local environ¬ 
ments, e.g. the mammalian epidermis. However, in i_n vitro cell 
cultures, achieving the same potential for intimate physical 
interaction that is provided by the inherent nature of epidermis, 
is no simple task. The critical nature of cellular interactions 
is manifest in experiments assaying for the production by sensitized 
T-cells of macrophage migration inhibitory factor (MIF). By increasing 
cellular density, and by permitting spontaneous sedimentation in 
a conical test tube, the MIF activity of a supernatant from cultures 
of lymphocytes and antigen was augmented [39,47,48] by a factor 
as great as 10^ [47]. The production of MIF was dependent on the 
presence of antigen (PPD) in the incubation with the sensitized 
cells; MIF activity was absent when antigen was incubated with 
non-sensitized cells. The amplification effect was abolished by 
dispersing the cell suspension over the large area of a flat- 
bottomed flask or by shaking the cell suspension. Thus the ampli¬ 
fied migration inhibition effect was negated by preventing pro¬ 
longed intimate cell-cell interactions. 
Using conical tubes and higher cell concentration for the 
incubation of PEC + PPD, Figure 7 shows significant inhibition of 
background release of serotonin (p<0.02) with a mean inhibition 
of 16%. Interestingly, this inhibition was significantly less than 
the inhibition observed in Figures 5 and 6 (p< 0.01), where the 
PEC were incubated at lower cell concentrations in flat-bottomed 
wells. It remains unclear whether the decrease amount of inhibition 
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in Figure 7 represents a decreased titer of an inhibitor, or an 
increased titer of a substance which causes serotonin release 
from mast cells. The addition of a prostaglandin synthesis inhibitor 
to the incubation of PEC in conical tubes at high cell concentrations 
may be able to uncover an agonist activity. 
Table 3 presents experiments in which various T-cell derived 
supernatants, known to contain different lymphokines, were incu¬ 
bated either directly with mast cells, or first with PEC and then 
3 ... 
with H-5HT labelled mast cells. The results are similar to Figure 7. 
In Table 3, there are different degrees of inhibition of back¬ 
ground serotonin release when the various T-cell supernatants were 
preincubated with PEC. As in Figure 7, this observation may repre¬ 
sent a decreased titer of an inhibitor or an increased titer of a 
factor with agonist activity. The addition of a prostaglandin 
inhibitor to the PEC cultures would again be or interest. 
The experiments in Figure 8 attempt to reproduce the SRBC 
model of DTH by interacting mast cells, sensitized T-cells (spleen 
cells four days after an optimal DTH elicitation SRBC dose), 
antigen-presenting macrophages (CFA-SRBC-PEC) and free antigen 
(SRBC). Proper cell-cell interaction is a major potential problem 
3 
with so many different cell types. In Figure 8a, the H-5HT labelled 
mast cells, spleen cells and PEC were pelleted to facilitate cell¬ 
cell contact and incubated for 90 minutes. In Figure 8c, the three 
types of cells were incubated for 24 hours. Figure 8a demonstrates 
modest enhancement of 5-HT release above background levels with 
either immune or normal spleen cells, though it is not statistically 
significant. Figure 8c, on the other hand, shows marked inhibition 

(45) 
of background 5-HT release with all the various combinations of 
PEC and spleen cells. 
This progression from modest enhancement of serotonin 
release apparent after a 90 minute incubation period to the signi¬ 
ficant inhibition seen after the 24 hour incubation period suggests 
the possibility that an inhibitory factor was produced over time. 
Different incubation periods between 90 minutes and 24 hours would 
be helpful in defining the time course of production of the potential 
inhibitor. As was discussed earlier, macrophages are known to pro¬ 
duce factors that can enhance immune responses and other factors 
that can inhibit them. It is possible that an agonist for 5-HT 
release may be produced early during the incubation period and 
the inhibitory activity becomes evident only later, masking the 
agonist activity. Prostaglandin synthesis inhibitors would also be 
valuable in these experiments by possibly unmasking an agonist 
activity. 
Identification of an IgE-like substance on the surface of mast cells 
The previous experiments are based on the hypothesis that 
mast cell activation occurs via a T-cell derived lymphokine or 
via an initial T-cell - macrophage interaction, with subseguent 
mast cell activation. Another hypothesis for T-cell - mast cell 
collaboration is that it occurs via IgE or an IgE-like material. 
There is a substantial amount of evidence that the mast cell 
activation and serotonin release leading to endothelial gap 
formation in the SRBC model of DTH is T-cell dependent, and not 
mediated by B-cell products such as IgE. In the actively sensitized 
animal challenged at day four to express DTH, there is little 
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evidence for B-cell activation as determined by antibodies to SRBC 
[ 6 ] or by induction of antigen binding rosette forming B-cells 
[14]. In addition, mice treated with anti-IgM antisera and rendered 
unable to produce antibodies are able to express DTH [12,35]. 
There is now evidence that T-cell membranes contain immuno¬ 
globulin-like molecules [43], which possess antigen binding 
properties [20]. If this T-cell "receptor" or a similar substance 
were able to be released from cells and attach to mast cells via 
an IgE-like activity, it may be able to trigger mast cell acti¬ 
vation by binding antigen. This reasoning about T-cell derived 
materials is speculative, but it should be considered, in light 
of the evidence against the participation of B-cells in the SRBC 
model of DTH, and in light of the results in Tables 4 and 5. 
The experiments performed in Tables 4 and 5 reveal the 
presence of an IgE-like substance on mast cells collected four 
days after mice were immunized with 0.01% SRBC, an optimal dose 
for DTH elicitation. In Table 4a, after incubation with a 
3 
1% suspension of sheep erythrocytes, the H-5HT release from 
these day four 0.01% SRBC mast cells was significantly greater 
3 
than the H-5HT release from normal mast cells (p< 0.02). 
3 ... 
However, the H-5HT release, after incubation with SRBC, from 
day 18 0.01% SRBC mast cells or from day four 10% SRBC mast 
3 
cells was not different from the H-5HT release from normal 
mast cells (Table 4b). As previously mentioned, the transient 
presence of the substance coating mast cells from mice immunized 
. 3 
with 0.01% SRBC and the baseline response (eguivalent to H-5HT 
release from normal mast cells incubated with 1% SRBC) of the 
day four 10% SRBC mast cells correspond remarkably closely to 
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the in vivo SRBC model of DTH [ 7 ]. in this model, optimal DTH 
responses are elicited from mice four days after 0.01% SRBC 
immunization, while poor DTH responses occur 18 days after 
0.01% SRBC immunization or four days after 10% SRBC immuni¬ 
zation. 
Thus it appears that there is an IgE-like factor on the 
surface of day four 0.01% SRBC mast cells which, upon exposure 
to antigen, SRBC, triggers 5-HT release. It is unlikely that this 
factor is an antibody; the other kinds of mast cells (day four 
10% SRBC and day 18 0.01% SRBC) from immunized animals would be 
expected to produce more antibody because of the higher immunization 
dose or the longer period of time between immunization and 
testing. The results with the day four 10% SRBC and the day 18 
0.01% SRBC mast cells need to be repeated to confirm that the 
5-HT release from these mast cells incubated with 1% SRBC is 
not significantly different from the 5-HT release from normal 
mast cells. 
Evidence supporting the hypothesis based on Table 4 that 
the IgE-like factor is distinct from conventional antibodies comes 
from the experiments in Table 5. The results in Table 5 show that 
the rabbit anti-mouse IgE and the goat anti-mouse IgG caused the 
3 
greatest H-5HT release when incubated with the day four 0.01% SRBC 
mast cells. These results are similar to the results of Table 4b 
where the SRBC also reacted maximally with the day four 0.01% SRBC 
mast cells. It is possible that the SRBC effect and the anti¬ 
immunoglobulin antibody effect may not be due to the same substance 
on the surface of the day four 0.01% SRBC mast cell. There was a 
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considerably lower level of H-5HT release from mast cells incubated 
with the goat anti-mouse IgG compared to the rabbit anti-mouse 
IgE. The goat anti-mouse IgG may not be specific for IgG and 
could be, to a limited extent, cross-reacting with light chain 
determinants in the IgE-like material. Decreased reagent purity 
and lower specific activity of the goat anti-mouse IgG preparation 
could also account for the low level of 5-HT release with the 
goat anti-mouse IgG. 
The rabbit anti-mouse IgE did react maximally with the 
day four 0.01% SRBC mast cells, but it also caused substantial 
^H-5HT release from the day four 10% SRBC and day 18 0.01% SRBC 
mast cells. The 5-HT release from the anti-mouse IgE incubation 
with the day four 10% SRBC or day 18 0.01% SRBC mast cells may 
result from the presence of conventional antibody on the surface 
of these mast cells. It is guite unlikely that more antibody 
would be present on the surface of the day four 0.01% SRBC mast 
cells because of the smaller immunization dose and the shorter 
time interval between immunization and testing compared to the 
other immune mast cells. Thus, as was previously seen with the 
incubations with 1% SRBC, it appears that an IgE-like material 
which reacts with antigen and with anti-mouse immunoglobulin, 
most likely not conventional antibody, is coating the surface of 
day four 0.01% SRBC mast cells. The experiments with the anti¬ 
immunoglobulin antibodies need to be repeated to confirm a 
significant difference for the four types of mast cells. The 
precise specificity of the anti-immunoglobulin antibodies also 
needs confirmation. 
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Further evidence against this IgE-like factor being a 
conventional antibody comes from the mast cells incubations with 
1% suspensions of horse erythrocytes. The day four 0.01% SRBC 
, . . 3 
mast cells had a significantly greater H-5HT release than normal 
mast cells, not only when incubated with SRBC (p40.02), but also 
when incubated with HRBC (p<.0.02) (Tables 4a and 4b). After 
3 
incubation with HRBC, the H-5HT release from day four 10% SRBC 
and day 18 0.01% SRBC mast cells was not significantly different 
from the 5-HT release from normal mast cells (Table 4b). Thus 
the day four 0.01% SRBC mast cells exhibit crossreactivity for HRBC 
In the SRBC model of murine DTH, there is some evidence 
for crossreactivity to HRBC. Mice immunized with 0.01% SRBC failed 
to express significant reactions whe footpad tested with HRBC in 
the usual challenge dose of a 20% erythrocyte suspension [ 7 ]. 
However, testing with 50% HRBC in mice immunized with SRBC did 
produce small but significant cross-reactive DTH responses [ 7 ]. 
Thus DTH reactions were specific but higher challenging doses 
could elicit cross-reactive DTH responses. Instead of incubating 
the day four 0.01% SRBC mast cells with 1% erythrocyte suspensions, 
it might be informative to use other erythrocyte dilutions, such 
as 0.1% and 0.01%, to determine whether the response to the homologous 
antigen would remain intact. Under these conditions, the cross¬ 
reactivity to HRBC might be eliminated. Mice could also be 
immunized with 0.01% HRBC to determine whether these mast cells 
would exhibit crossreactivity for SRBC. 
Delayed hypersensitivity responses to various proteins 
often show cross-reactions between antigens that do not cross- 
react with the specific antibody [21,46 ,51]. In one system, 
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DTH responses were measured after guinea pig immunization to 
horse cytochrome c protein. The animals were subseguently skin 
tested with cytochrome c from horse and other species. It was 
found that significant cross-reactions existed when there were 
only minor amino acid seguence differences between the horse 
cytochrome c and the cytochrome c of the species skin tested [51]. 
There was less cross-reactivity when there were more differences 
between the aminoacid sequences. It is interesting that a high 
degree of specificity has been shown in DTH reactions involving 
haptenated proteins such as dinitrophenyloligolysine [54]. The 
flagellin proteins from two different species of Salmonella, 
although observed to produce very weakly cross-reacting anti¬ 
bodies, had strongly cross-reactive DTH responses [46]. 
Similar cross-reactivity has been reported to occur between serum 
albumins [21]. In a system studying a different T-cell function, 
there was extensive cross-reactivity in the cytotoxic T-cell 
response to a variety of serologically distinct influenza A 
viruses [19], Thus there is data to suggest cross-reactivity 
of T-cells in delayed hypersensitivity while it is generally 
accepted that antibodies only react with the one specific antigen. 
The cross-reactivity of the IgE-like factor coating the 
day four 0.01% SRBC mast cells thus provides additional, although 
by no means firm, evidence against the factor being a conventional 
antibody. The IgE-like factor is reacting with some antigenic 
determinant or component of the horse and sheep erythrocyte, 
an interaction that results in mast cell activation and serotonin 
release. Erythrocytes from other species, such as goats and 
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humans should also be incubated with the day four 0.01% SRBC 
mast cells to determine the extent of the cross-reactivity. 
The IgE-like factor thus has properties that are not 
characteristic of antibodies: cross-reactivity, lack of appearance 
after antibody inducing immunization doses, and transient presence 
after DTH eliciting doses. These properties are actually more 
analogous to a hypothetical T-cell derived mediator of DTH. 
These properties, when combined with the evidence against the 
participation of B-cells in DTH, suggest that this factor could 
be a T-cell derived product which possesses the ability to inter¬ 
act with antigen. 
Summary 
The present study has attempted to identify in_ vitro 
T-cell interaction with mast cells that results in the release 
of serotonin. Experiments with peritoneal exudate cells revealed 
the presence of an inhibitor of background (spontaneous) serotonin 
release from mast cells along with some indirect evidence for the 
presence of a substance that could actually induce serotonin 
release or inhibitor inactivation. Many possible approaches for 
further investigation have already been discussed. Further 
characterization of the inhibitory activity might involve incu¬ 
bation of the PEC supernatants with compound 48/80 or with antibody 
and antigen to determine whether the inhibitory factor was also 
active against the ability of well characterized agonists to 
mediate serotonin release. Other experiments performed identified 
an IgE-like substance on the surface of mast cells from mice 
immunized to optimally express DTH. This substance interacted 
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with a multivalent antigen and with anti-mouse IgE and anti¬ 
mouse IgG. Arguments were presented that this substance could 
be derived from T-cells. However, it is conceivable that this 
substance is IgE. It may be preferentially induced by immunization 
with low antigen doses, and it may possess a short half life. 
Further study of this IgE-like substance might include 
identifying its presence in mice rendered agammaglobulinemic by 
treatment with anti-IgM antisera. Other types of antigen, such 
as protein or other particulate antigens, could be used to 
immunize mice and test whether the cross-reactivity is simply 
a function of the geometry or inherent similarities between 
SRBC and HRBC. Additionally, different kinds of anti-immuno¬ 
globulin antibodies, such as anti-idiotypic antibodies, could 
be used to further elucidate the nature of the IgE-like 
material. Recently, antibodies have also been produced against 
antigen specific T-cell derived molecules [43]. Such antibodies 
could also be incubated with day four 0.01% SRBC mast cells. 
It has recently been revealed that mast cells, when 
treated with amitriptyline and other psychotropic agents, can 
secrete serotonin in the absence of histamine release and in 
the absence of overt degranulation [8]. Tritiated serotonin 
release was measured exclusively in the present study. Mast 
cells' capacity for this differential release has not yet been 
identified in any physiologic system. It would be of interest 
to assay for concommitant histamine release from the incubation 
of day four 0.01% SRBC mast cells and antigen or anti-immuno 
globulin antibody. 
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FIGURE 1; Photographs of mouse mast cells stained with 
Wright-Giemsa. Note the large number of purple- 
staining granules in the cytoplasm of the mast cell* 
Other cells are lymphocytes and other mononuclear 
cells. Magnification x 400. 
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FIGURE 2; Photograph of mouse peritoneal exudate cells, 
induced by complete Freund’s adjuvant. Note large 
mononuclear cell with vacuolated cytoplasm Other 
cells are neutrophils<= Magnification x 400. 

3 
FIGURE 3: Background (spontaneous) release of H-serotonm 
in Locke's solution as a function of the age of 
the serotonin preparation* 
3 . 
* H-serotonm labelled mast cells were incubated m 
Locke's solution for 90 minutes at 37°Co The age of the 
serotonin preparation represents the number of days after 
delivery from New England Nuclear. The line drawn represent 
the linear regression line. 
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FIGURE 4: 3 H-serotonin release from mast cells as a function 
of the concentration of compound 48/80* 
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* H-serotonin labelled mast cells were incubated with 
compound 48/80 at the indicated concentrations for 90 minutes 
at 37°C. 
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Table 1: 
3 
H-serotonin release from mast cells incubated with 
ovalbumin induced supernatants* 
Type of Supernatant dilutions 
supernatant 1:2 1:20 1:200 
OVA + LNC in a plate 6.6% 4.0% 4.0% 
OVA + LNC in conical 
tubes 6.1% 4.2% 
4.0% 
Media 5.1% 4.1% 4.0% 
♦Supernatants were generated from a 24 hour incubation, in a 
plate or conical tube^ of 250ug/ml ovalbumin (OVA) with 
2 x 10^ inguinal lymph node cells (LNC)/ml. The lymph node cells 
were obtained from C57 female mice, 8 days after subcutaneous 
immunization in the tail of 50ug OVA + complete Freund's adjuvant. 
Aliquots of the supernatants and media were then diluted in 
Locke's solution and incubated with ^H-5HT labelled mast cells 
for 90 minutes at 37°C. 
Table 2* ^H-serotonin release from mast cells incubated with 
T-cell lymphoma and hybridoma supernatants* 
Type of Supernatant dilutions 
supernatant 1:2 * 1:100 
BW 5147 with serum 6.9% 4.9% 
BW 5147 without serum 7.5% 4.7% 
64C11 with serum 5.7% 4.7% 
64C11 without serum 6.9% 5.3% 
Media 7.3% 5.1% 
♦Supernatants were generated from T-cell lymphoma 
and hybridoma (64C11) cell lines supplied by Dr. Nancy Ruddle. 
These cells were incubated without antigen for 48 hours. Aliquots 
of the supernatants and media were then diluted in Locke's 
solution and incubated with ^H-5HT labelled mast cells for 
90 minutes at 37°C. 
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FIGURE 5: ^H-serotonin release from 
supernatants from CFA-PEC 
mast cells incubated with 
or IFA-PEC + PPD* 
IPPD) 
Figure 5b 
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FIGURE 6» H-serotonin release from mast cells incubated with 
supernatants from 5 day or 9 day CFA-PEC + PPD* 
Figure 6a 
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*5 day or 9 day CFA-PEC + PPD were incubated 48 hours at 37°C. 
in wells. Then a 0.5ml aliquot of the supernatant was incubated with 
•^H-serotonin labelled mast cells for 90 minutes at 37°C. 
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FIGURE 7: 3H-serotonin release from mast cells incubated with 
supernatants from 5 day, 11 day, and 24 day CFA-PEC 
+ PPD* 
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Figure 7b 
Supernatant 
dilution 
% release 
% 
Inhibition 
1:2 
CN
 6.2 
- 14% 
rd u 
•H >1 w 
d P 
a1 TS 1 
£ <c in p 
u 
1:20 
Q 
P 
P 
+ 
Q 
P 
P 
+ 
1:200 
5.1 4.1 
- 
20% 
rd a 
•H w 
73 d p 
0) TS 1 
E <c 
in p 
U 
+ + 
Q 
P 
P 
O o o 
*5 day, 11 day, 24 day CFA-PEC + 50 ug/ml PPD were incubated 
48 hours ®> 37°C. in conical tubes, 15-20 x 10^cells/ml. Then 3h-5HT 
labelled mast cells and different supernatant dilutions, 1:2, 1:20, 1:200, 
were incubated 90 minutes at 37°C. 
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3 . . 
Table 3: H-serotomn release from mast cells incubated with 
T-cell derived supernatants and with supernatants 
generated from the incubation of these T-cell super¬ 
natants with peritoneal exudate cells* 
Supernatant 
incubated with T-cell derived supernatant 
mast cells 1 2 3 4 5 6 7 8 Media 
cell supernatant 7.6% 5.5% 7.6% 4.5% 5.5% 5.0% 5.4% 5.4% 7.4% 
Supernatant 
+ CFA-PEC 3.3% 4.0% 4.3% 3.5% 4.7% 4.1% 4.8% 4.8% 4.5% 
Supernatant 
+ IFA-PEC 4.5% 4.1% - 4.2% 4.0% - - - 3.9% 
Mean inhibition 
for supernatant 
+ PEC 
49% 26% 43% 15% 21% 18% 11% 11% 43% 
*T-cell derived 
Dr. Charles Janeway; 
supernatants 
supernatants 
#1 - 
#6 - 
#5 were 
#8 were 
obtained 
obtained 
from 
from 
Drs. Monte Meltzer and Edward J. Leonard. The original T-cell 
supernatants and media control were incubated with ^H-5HT 
labelled mast cells for 90 minutes at 37°C. T-cell supernatants 
were also incubated with 3 day CFA-PEC and IFA-PEC, 7 x 10^ cells/ml 
in wells for 24 hours at 37°C. Then aliquots of the supernatant - PEC 
were incubated with ^H-5HT labelled mast cells for 90 minutes at 
37°C. 
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FIGURE 8as 
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*5 day CFA-SRBC-PEC - 7 x 106/ml and spleen cells - 7 x 10 /ml 
(4 days after 0.01% SRBC or 4 days after 10% SRBC immunization or 
after saline injection) and JH-5HT labelled mast cells -lx 105/ml 
were pelleted in round-bottomed test tubes and incubated 90 minutes 
at 37°C. 
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FIGURE 8b: 
3 
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release after incubation of mast cells, 
spleen cells and antigen* 
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* 5 day CFA-SRBC-PEC - 7 x 10 /ml and 4 day .01, 10, normal 
spleen cells - 7 x lO^/ml were incubated in tubes for 24 hours 
at 37oCo Then the supernatant and non-adhered cells were poured off. 
•^H“5HT labelled mast cells were spun down onto the adhered cells 
and incubated 90 minutes at 37°C. 
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FIGURE 8c; H-serotonin release after incubation of mast cells, 
macrophages, spleen cells and antigen* 
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*The different combinations of PEC (macrophages), spleen 
cells (T-lymphocytes) and mast cells were incubated as in 
Figure 8a except that all the types of cells were incubated for 
24 hours at 37°C. 

3 
TABLE 4: H-5HT release after interaction between sheep or 
horse erythrocytes and mast cells from normal or 
immunized mice* 
Table 4a: 
Antigen + mast cells 
Incubation conditions for mast cells + RBC 
Settling; 
90min (§> 37°C 
Pelleted; 
45min d> 4°C, 
45min @ 37°C 
Settling; 
45min d> 4°C, 
45min t> 37°C 
SRBC + day 4 .01% SRBC 
mast cells 
SRBC + normal 
mast cells 
15.1% + 1.1 28.3% 
11.3% + 2.7 14.6% 
+7.0 16.6% +4.1 
+5.7 11.5% + 1.1 
HRBC + day 4 .01% SRBC 
mast cells 
HRBC + normal 
mast cells 
13.8% 
10.5% 
14.7% 
11.2% 
17.3% + 2.6 
12.6% + 1.6 
Table 4b: 
Mast cells 
Antigen 
SRBC HRBC 
day 4 .01% SRBC 
mast cells 
16.6% + 4.1 
(n=8) 
17.3% + 2.6 
(n=6) 
normal 
mast cells 
11.5% + 1.1 
(n=6) 
12.6% + 1.6 
(n=4) 
day 18 .01% SRBC 
mast cells 
9.6% 
day 4 10% SRBC 
mast cells 
10.7% 12.2% 
*1% erythrocyte suspensions were incubated with various kinds 
of mast cells. Mast cells were collected 4 or 18 days after mice were 
immunized with .01% SRBC. Mast cells were also collected 4 days after 
mice were immunized with 10% SRBC. Mast cells from normal mice were 
also used. Incubation conditions were as described in Table 4a. In 
Table 4b, all erythrocytes + mast cells were incubated settling in tubes, 
90 minutes at 37°C. Values are mean ^H-5HT release + standard deviation. 
Number of experiments, n, comprising each mean is indicated in 
parenthesis. 

3 . 
TABLE 5; H-serotonm release from mast cells from immunized 
animals after treatment with anti-immunoglobulin antibody* 
anti-DNP IgE 
rabbit + rabbit goat 
anti-mouse anti-mouse anti-mouse 
Mast cells SRBC HRBC IgE 
day 4 .01% SRBC 
mast cells 
16.6% 17.3% 28.6% 
day 18 .01% SRBC 
mast cells 
8.2% 9.6% 8.1% 
day 4 10% SRBC 
mast cells 
10.7% 12.2% 18.3% 
normal 
mast cells 
11.5% 12.6% 4.2% 
IgE IgG 48/80 
32.1% 5.3% 26.0% 
30.3% 2.7% 31.9% 
23.5% 1.5% 29.3% 
10.2% 2.9% 28.8% 
*The different mast cells were incubated with erythrocytes for 
90 minutes at 37°C., as described in Table 4. The mast cells were also 
incubated with 48/80, 20 ug/ml, for 90 minutes at 37°C. The mast cells 
were incubated in Locke's solution for 45 minutes and then with rabbit 
anti-mouse IgE or with goat anti-mouse IgG for 45 minutes. The mast 
cells were also first incubated with anti-DNP IgE for 45 minutes. 
The assay tubes were then spun, the supernatant was poured off and 
the pellet was brought up in Locke's solution and incubated with 
anti-mouse IgE for an additional 45 minutes. 
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